Celgene upgraded to Buy from Neutral at UBS UBS upgraded Celgene based on less perceived risk ahead of upcoming data at this weekends ASH meeting. The firm believes Revlimid will be "out of the woods" with a clean MM-020 result in terms of regulatory and clinical risk. Price target raised to $200 from $163.
News For CELG From The Last 14 Days
Check below for free stories on CELG the last two weeks.